Katalog der Deutschen Nationalbibliothek

Springe direkt zu:

Katalog (Beta)

Wissensnetz

Person
Person

Person

Sandra Ciesek (1978-)

Virologin

Name

Sandra Ciesek

Zeit

1978- (Lebensdaten)

Ort

Goslar (Geburtsort)
Hannover (Wirkungsort)
Deutschland

Geschlecht

weiblich

Akademischer Grad bzw. Titel

Prof. Dr. med.

Beruf

Virologin (charakteristischer Beruf)
Ärztin

Variante

S. Ciesek

Beziehung

Themen­gebiet

Personen zu Medizin, Tiermedizin

Weitere Angaben

Diss. Medizin Medizinische Hochschule Hannover (2004); Habil. Fach Experimentelle Gastroenterologie an der Medizinischen Hochschule Hannover (2010). Forschungsschwerpunkte: neue Therapieformen für Hepatitis C und medikamentöse Therapien gegen COVID-19

Quelle

Kürschner Gelehrte (J)

Datensatztyp

Person

GND-Nummer

129438723

Datensatz-ID

129438723

Beteiligt an

alle anzeigen

Characterization of antiviral effects of emricasan and SARS-CoV-2 isolates in vitro

Pediatric cancer patients vaccinated against SARS-CoV-2—a clinical and laboratory follow-up

Etablierung der Genomischen Erreger-Surveillance zur Stärkung des Pandemie- und Infektionsschutzes in Deutschland

A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection

An appeal for strengthening genomic pathogen surveillance to improve pandemic preparedness and infection prevention: the German perspective

Corrigendum: SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines

Etablierung der Genomischen Erreger-Surveillance zur Stärkung des Pandemie- und Infektionsschutzes in Deutschland = Establishment of genomic pathogen surveillance to strengthen pandemic preparedness and infection prevention in Germany

Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform

Identification of Z-Tyr-Ala-CHN2, a cathepsin L inhibitor with broad-spectrum cell-specific activity against coronaviruses, including SARS-CoV-2

Repurposing of the antibiotic nitroxoline for the treatment of mpox

Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients

SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines

SARS-CoV-2 variants show different host cell proteome profiles with delayed immune response activation in Omicron-infected cells

Untersuchung zur Beteiligung von Kindern in hessischen Kindertagesstätten am Infektionsgeschehen während der SARS-CoV-2-Pandemie: Ergebnisse der SAFE-KiDS-Studie

The spike gene is a major determinant for the SARS-CoV-2 Omicron-BA.1 phenotype

Wie geht es mit der Pandemie im Winter weiter? : Fragen an Prof. Sandra Ciesek

Suitability of Different Diagnostic Platforms for Virological Testing of Blood Samples from Cornea Donors

Development and optimisation of a high-throughput screening assay for in vitro antiSARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures

Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: Evaluation of 5676 Phase 1 Passed Structures

Early detection of SARS-CoV-2 Omicron BA.4 and BA.5 in German wastewater

Early Detection of SARS-CoV-2 Omicron BA.4 and BA.5 in German Wastewater

Early Detection of SARS-CoV-2 Omicron BA.4 and BA.5 in German Wastewater

Early detection of SARS-CoV-2 Omicron BA.4/5 in German wastewater

Early detection of SARS-CoV-2 Omicron BA.4/5 in German wastewater

Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study

Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform

Impact of Moderna mRNA-1273 booster vaccine on fully vaccinated high-risk chronic dialysis patients after loss of humoral response

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Long-term immune protection against SARS-CoV-2 escape variants upon a single vaccination with murine cytomegalovirus expressing the spike protein

Low but recoverable markers of humoral immune response to BNT162b2 in elderly LTCF residents five to seven months after two-dose vaccination

Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes

Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response

Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response

Omicron-induced interferon signalling prevents influenza A virus infection

Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates

Repurposing of the antibiotic nitroxoline for the treatment of mpox

SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment

SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment

SARS-CoV-2 screening strategies for returning international travellers: Evaluation of a rapid antigen test approach

SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccination

Suitability of different diagnostic platforms for virological testing of blood samples from cornea donors

Suitability of different diagnostic platforms for virological testing of blood samples from cornea donors

Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants

Wastewater surveillance allows early detection of SARS-CoV-2 omicron in North Rhine-Westphalia, Germany

Wastewater surveillance allows early detection of SARS-CoV-2 omicron in North Rhine-Westphalia, Germany

Powered air-purifying respirators used during the SARS-CoV-2 pandemic significantly reduce speech perception

Detection and infectivity of SARS-CoV-2 in exhumated corpses

Increased susceptibility of human endothelial cells to infections by SARS-CoV-2 variants

Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings

Typical symptoms of common otorhinolaryngological diseases may mask a SARS-CoV-2 infection

Infectivity of deceased COVID-19 patients

A potential role of the CD47/SIRPalpha axis in COVID-19 pathogenesis

Antibody-mediated neutralization of authentic SARS-CoV-2 B.1.617 variants harboring L452R and T478K/E484Q

Antibody-mediated neutralization of authentic SARS-CoV-2 B.1.617 variants harboring L452R and T478K/E484Q

Antibody-mediated neutralization of authentic SARS-CoV-2 B.1.617 variants harboring L452R and T478K/E484Q

CD47 as a potential biomarker for the early diagnosis of severe COVID-19

Characterization of ACE inhibitors and AT1R antagonists with regard to their effect on ACE2 expression and infection with SARS-CoV-2 using a Caco-2 cell model

COVID-19 among children seeking primary paediatric care with signs of an acute infection

COVID-19 among children seeking primary paediatric care with signs of an acute infection

Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings
Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

DNB-Portal